Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Orthofix Medical ( (OFIX) ) is now available.
Orthofix Medical reported first-quarter 2026 results on May 5, 2026, showing reported net sales of $196.7 million and pro forma net sales of $196.4 million, up 2.7% year over year on a constant currency basis excluding its discontinued M6 disc lines. Segment performance was solid, with Global Spine Fixation growing 6%, Therapeutic Solutions up 5%, and Global Limb Reconstruction rising 10% in reported net sales, while GAAP gross margin reached 70.9% and net loss narrowed to $20.9 million compared with a $53.1 million loss a year earlier.
Management highlighted that distributor transitions in the spine business are largely complete, underpinning expectations for more consistent commercial execution and margin improvement over the rest of 2026. The company reaffirmed full-year 2026 guidance, projecting net sales of $850 million to $860 million, non-GAAP adjusted EBITDA of $95 million to $98 million, and positive free cash flow, supported by targeted innovation, spine leadership changes, and planned product launches intended to strengthen its competitive position and long-term shareholder value.
The most recent analyst rating on (OFIX) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Orthofix Medical stock, see the OFIX Stock Forecast page.
Spark’s Take on OFIX Stock
According to Spark, TipRanks’ AI Analyst, OFIX is a Neutral.
The score is held back primarily by weak current profitability and negative free cash flow despite strong revenue growth and healthy gross margins. The earnings call improves the outlook with guidance for margin expansion and positive 2026 free cash flow (excluding legal items), but technicals remain mixed-to-soft with price below key moving averages and negative MACD, and valuation is difficult to assess due to losses and no dividend support.
To see Spark’s full report on OFIX stock, click here.
More about Orthofix Medical
Orthofix Medical Inc., based in Lewisville, Texas, is a global medical technology company focused on treating complex musculoskeletal conditions. The company offers a portfolio that includes spinal implants, therapeutic solutions, limb reconstruction systems, biologics and enabling technologies, targeting improved clinical outcomes and more efficient care across the continuum of musculoskeletal treatment.
Average Trading Volume: 272,259
Technical Sentiment Signal: Strong Sell
Current Market Cap: $482.1M
Find detailed analytics on OFIX stock on TipRanks’ Stock Analysis page.